Statement on the Clinical Use of Recombinant Erythropoietin in Anemia of End-Stage Renal Disease
- 1 September 1989
- journal article
- review article
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 14 (3) , 163-169
Abstract
No abstract availableThis publication has 35 references indexed in Scilit:
- Do polyamines play a role in the pathogenesis of the anemia of end-stage renal disease?Kidney International, 1989
- Use of subcutaneous recombinant human erythropoietin in children undergoing continuous cycling peritoneal dialysisThe Journal of Pediatrics, 1989
- The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietinKidney International, 1989
- SUBCUTANEOUS ERYTHROPOIETINThe Lancet, 1988
- Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney.Journal of Clinical Investigation, 1988
- Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis.BMJ, 1987
- EFFECT OF HUMAN ERYTHROPOIETIN DERIVED FROM RECOMBINANT DNA ON THE ANAEMIA OF PATIENTS MAINTAINED BY CHRONIC HAEMODIALYSISThe Lancet, 1986
- Isolation and characterization of genomic and cDNA clones of human erythropoietinNature, 1985
- Identification of Spermine as an Inhibitor of Erythropoiesis in Patients with Chronic Renal FailureJournal of Clinical Investigation, 1981
- Hemodynamics of Uremic AnemiaCirculation, 1971